Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRADE DXd: Sequential Dato-DXd and T-DXd in Metastatic HER2-negative Breast Cancer
NCT06533826Phase 2Recruiting
- Sponsor
- Ana C. Garrido-Castro
- Start
- Oct 2024
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of datopotamab deruxtecan, trastuzumab deruxtecan in breast cancer, sponsored by Ana C. Garrido-Castro. Started Oct 2024; status: recruiting.
02
Drugs
datopotamab deruxtecantrastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06533826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533826.